Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 9;62(3):2300950.
doi: 10.1183/13993003.00950-2023. Print 2023 Sep.

"Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials

Anthony Byrne  1   2 , Brian Allwood  3 , Ingrid Schoeman  4 , James Johnston  5   6 , Gautam Kalyatanda  7 , Goodman Makanda  8 , Kevin Mortimer  9 , Carole Mitnick  10 , Rebecca Nightingale  9 , Obianuju Ozoh  11 , Andrea Rachow  12 , Marieke Van Der Zalm  2   13
Affiliations
Comment

"Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials

Anthony Byrne et al. Eur Respir J. .

Abstract

New TB treatment regimens are a welcome advancement. However, for the millions of TB survivors with impaired lung function and quality of life, more holistic outcome measures and the inclusion of lung function is essential in future TB treatment trials. https://bit.ly/3PWT0o2

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A. Byrne reports honoraria for lectures from GSK, AstraZeneca and Pfizer, and travel support from Qiagen to attend the Asian TB expert meeting in April 2023. B. Allwood reports honoraria for lectures from Janssen Pharmaceuticals, Boehringer Ingelheim, GSK, Novartis, Pfizer and Cipla. R. Nightingale reports support for PhD and research from Medical Research Council, UK, and support for research projects from Liverpool School of Tropical Medicine. A. Rachow reports support for research projects from the German Ministry for Education and Research, German Centre for Infection Research and the Bavarian State. M. Van Der Zalm reports a career development grant from EDCTP2 program, supported by the European Union, and from the Fogarty International Centre of NIH (K43TW011028). The remaining authors have no potential conflicts of interest to disclose.

Comment on

References

    1. Ivanova O, Hoffmann VS, Lange C, et al. . Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people. Eur Respir Rev 2023; 32: 220221. Doi:10.1183/16000617.0221-2022 - DOI - PMC - PubMed
    1. Allwood BW, Byrne A, Meghji J, et al. . Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration 2021; 100: 751–763. Doi:10.1159/000512531 - DOI - PubMed
    1. Migliori GB, Marx FM, Ambrosino N, et al. . Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis 2021; 25: 797–813. Doi:10.5588/ijtld.21.0425 - DOI - PMC - PubMed
    1. Dodd PJ, Yuen CM, Jayasooriya SM, et al. . Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis 2021; 21: 984–992. Doi:10.1016/S1473-3099(20)30919-1 - DOI - PubMed
    1. Dorman SE, Nahid P, Kurbatova EV, et al. . Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 2021; 384: 1705–1718. Doi:10.1056/NEJMoa2033400 - DOI - PMC - PubMed